Literature DB >> 17681738

Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.

Lizhi He1, Catherine Fan, Aubrey Gillis, Xinchang Feng, Michael Sanatani, Sebastien Hotte, Anil Kapoor, Damu Tang.   

Abstract

Recruiting Akt to the membrane-bound phosphatidylinositol (3,4,5) trisphosphate (PIP3) is required for Akt activation. While PI3 kinase (PI3K) produces PIP3, PTEN dephosphorylates the 3-position phosphate from PIP3, thereby directly inhibiting Akt activation. PTEN is the dominant PIP3 phosphatase, as knockdown of PTEN results in increases in Akt activation in mice. The PTEN tumor suppressor gene is frequently mutated in a variety of human cancers, consistent with an inverse correlation between levels of the PTEN protein and Akt activation. We have examined PTEN expression and Akt activation in 35 primary clear cell renal cell carcinomas RCCs (ccRCCs) and 9 papillary RCCs (pRCCs) and their respective non-tumor kidney tissues. The PTEN protein was reduced in 16 ccRCCs (16/35=45.7%) and 8 pRCCs (8/9=88.9%). In these RCCs, 25.0% (4/16) of ccRCCs and 25.0% (2/8) of pRCCs expressed elevated Akt activation. 19 ccRCCc (19/35=54.3%) expressed comparable or higher levels of PTEN. Of these ccRCCs, 31.6% (6/19) showed increases in Akt activation. As PTEN dominantly inhibits Akt activation, the coexistence of high levels of the PTEN protein with enhanced Akt activation suggests the existence of novel mechanisms which attenuate PTEN function in ccRCC. These mechanisms may reduce PTEN function or increase PIP3 production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681738     DOI: 10.1016/j.bbadis.2007.07.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.

Authors:  Anoma Nellore; Bianling Liu; Nikolaos Patsoukis; Vassiliki A Boussiotis; Lequn Li
Journal:  Clin Immunol       Date:  2014-03-12       Impact factor: 3.969

3.  Mesodermal Pten inactivation leads to alveolar capillary dysplasia- like phenotype.

Authors:  Caterina Tiozzo; Gianni Carraro; Denise Al Alam; Sheryl Baptista; Soula Danopoulos; Aimin Li; Maria Lavarreda-Pearce; Changgong Li; Stijn De Langhe; Belinda Chan; Zea Borok; Saverio Bellusci; Parviz Minoo
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells.

Authors:  Lizhi He; Catherine Fan; Anil Kapoor; Alistair J Ingram; Adrian P Rybak; Richard C Austin; Jeffery Dickhout; Jean-Claude Cutz; James Scholey; Damu Tang
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

5.  p-AKT overexpression in primary renal cell carcinomas and their metastases.

Authors:  Martina Hager; Heike Haufe; Lukas Lusuardi; Nikolaus Schmeller; Christian Kolbitsch
Journal:  Clin Exp Metastasis       Date:  2010-09-16       Impact factor: 5.150

6.  PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.

Authors:  Brenda L Petrella; Constance E Brinckerhoff
Journal:  Cancer Biol Ther       Date:  2009-07-30       Impact factor: 4.742

7.  PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

Authors:  Nikolaos Patsoukis; Lequn Li; Duygu Sari; Victoria Petkova; Vassiliki A Boussiotis
Journal:  Mol Cell Biol       Date:  2013-06-03       Impact factor: 4.272

8.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.

Authors:  Ana Silva; J Andrés Yunes; Bruno A Cardoso; Leila R Martins; Patrícia Y Jotta; Miguel Abecasis; Alexandre E Nowill; Nick R Leslie; Angelo A Cardoso; Joao T Barata
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

9.  Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.

Authors:  Cheng-Ping Yu; Jar-Yi Ho; Yi-Ting Huang; Tai-Lung Cha; Guang-Huan Sun; Dah-Shyong Yu; Fung-Wei Chang; Shu-Pin Chen; Ren-Jun Hsu
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  Regulation of axonal growth and neuromuscular junction formation by neuronal phosphatase and tensin homologue signaling.

Authors:  Pan P Li; H Benjamin Peng
Journal:  Mol Biol Cell       Date:  2012-08-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.